FHTX Stock Extends Sell-Off After Eli Lilly Collaboration Ends
Foghorn Therapeutics (FHTX) shares dropped over 28% on Friday, extending a previous day's 18% slump, following the termination of its cancer-drug collaboration with Eli Lilly (LLY). The biotech firm announced it would cease development of FHD-909.
Shares of Foghorn Therapeutics (FHTX) dropped more than 28% on Friday, extending an 18% decline from the prior session, after Wall Street turned cautious when the biotech company ended its cancer-drug collaboration with Eli Lilly (LLY). On Thursday, Foghorn said it would stop developing FHD-909, an experimental cancer drug.